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Abstract
Background: Targeted therapies are becoming an essential part of breast cancer treatment and agents targeting
the type I insulin-like growth factor receptor (IGF-IR) are currently being investigated in clinical trials. One of the
limitations of targeted therapies is the development of resistant variants and these variants typically present with
unique gene expression patterns and characteristics compared to the original tumor.
Results: MTB-IGFIR transgenic mice, with inducible overexpression of the IGF-IR were used to model mammary
tumors that develop resistance to IGF-IR targeting agents. IGF-IR independent mammary tumors, previously shown
to possess characteristics associated with EMT, were found to express elevated levels of PDGFRa and PDGFRb.
Furthermore, these receptors were shown to be inversely expressed with the IGF-IR in this model. Using cell lines
derived from IGF-IR-independent mammary tumors (from MTB-IGFIR mice), it was demonstrated that PDGFRa and
to a lesser extent PDGFRb was important for cell migration and invasion as RNAi knockdown of PDGFRa alone or
PDGFRa and PDGFRb in combination, significantly decreased tumor cell migration in Boyden chamber assays and
suppressed cell migration in scratch wound assays. Somewhat surprisingly, concomitant knockdown of PDGFRa
and PDGFRb resulted in a modest increase in cell proliferation and a decrease in apoptosis.
Conclusion: During IGF-IR independence, PDGFRs are upregulated and function to enhance tumor cell motility.
These results demonstrate a novel interaction between the IGF-IR and PDGFRs and highlight an important,
therapeutically relevant pathway, for tumor cell migration and invasion.
Keywords: IGF-IR, PDGFR, Breast cancer, Migration, Resistance
Background
Targeting receptor tyrosine kinases (RTKs) for the treat-
ment of breast cancer has emerged as a promising direc-
tion for the management of this disease. However, a
major drawback of this line of treatment is the propen-
sity of tumors to acquire resistance. For example, a
number of mechanisms have been identified as media-
tors of resistance to the commonly used Her2-directed
therapeutic trastuzumab (reviewed in [1]). Therefore, a
powerful tool for overcoming this shortcoming and
optimizing the use of such compounds will be under-
standing mechanisms of resistance.
The insulin-like growth factor (IGF)-axis comprises
one such RTK signalling pathway heavily implicated in
the progression of breast cancer and as such holds pro-
mise for therapeutic targeting. Upon activation by ligand
(IGF-I or IGF-II), the IGF-IR undergoes tyrosine phos-
phorylation, subsequently signaling through a number of
downstream pathways including MAPK and PI-3K/Akt.
The mitogenicity of this receptor is well established, and
is well known to contribute to transformation of normal
mammary epithelial cells [2]. Effective targeting of this
pathway was established in a number of xenograft mod-
els of breast cancer [3-7]. Activation of the IGF-IR is
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cancer [8] and therefore offers the opportunity for
widespread use of targeted therapies. Based on these
observations, a number of drugs targeting this pathway
are currently in clinical trials [9,10], including small
molecule kinase inhibitors that block downstream sig-
nalling and monoclonal antibodies that block ligand
receptor interactions [11]. While it is too early to
determine the efficacy of such agents [9], it is of
extreme importance to understand potential resistance
mechanisms.
Previously our lab has created an inducible transgenic
mouse model (MTB-IGFIR) of IGF-IR overexpression in
which mammary tumors were observed to develop [12].
IGF-IR transgene downregulation resulted in regression
of almost all established palpable tumors after which a
fraction recur in the absence of IGF-IR induction [13].
Thus, this model recapitulates treatment with IGF-IR-
directed therapeutics and can be used to study potential
resistance mechanisms. Previous work has provided
initial characterization of IGF-IR-independence and has
demonstrated the presence of an epithelial-mesenchymal
transition (EMT) phenotype in these recurrent tumors
[13]. Subsequent microarray data, comparing primary
mammary tumors to IGF-IR-independent recurrent
tumors, has since identified members of the platelet-
derived growth factor family (PDGF) as being upregu-
lated during this process [14].
T h ei m p o r t a n c eo fP D G Fr e c e p t o r s( P D G F R s )i sw e l l
known in gliomas, sarcomas and gastrointestinal stro-
mal tumors but has more recently been noted in such
cancers as ovarian, prostate and neuroblastomas
(reviewed in [15,16]). However, compared to other
RTKs, little is known about the role of these proteins
in breast cancer. Signalling through PDGFRs has been
typically associated with proliferation and migration of
mesenchymal cells and is important for these processes
during mammalian development (reviewed in [17]).
Through downstream mediators such as MAPK, FAK,
PI-3K, Src and PLC-g,P D G F R sa l s og o v e r np r o c e s s e s
such survival, proliferation and angiogenesis (reviewed
in [15,18]). The best understood ligands for these
receptors include PDGF-A and B which undergo
homo- or heterodimerization to become active [16]. In
breast cancer, expression of PDGFRs was initially
shown to be restricted to the tumor stroma, while
ligand was produced by the tumor cells [19,20]. How-
ever, recent evidence suggests that expression of both
PDGFRa and b, either in the tumor tissue or stroma,
is correlated with invasive breast cancers and tumor
progression [21-23]. In addition, PDGFRa was shown
to be important for maintenance of EMT, evasion of
apoptosis, and metastasis in transformed mesenchymal
murine mammary cells [22].
T h ep u r p o s eo ft h i ss t u d yw a st oe x a m i n et h er o l eo f
the PDGF-axis in mammary tumors that survive inde-
pendent of IGF-IR signaling in MTB-IGFIR mice. Upon
IGF-IR suppression, expression of PDGFRa and b were
observed to increase, a process which occurred rapidly.
In cell lines isolated from IGF-IR-independent recurrent
tumors, PDGFRs were shown to facilitate motility and
invasion with more modest effects on proliferation and
apoptosis.
Materials and methods
Animal studies
MTB-IGFIR transgenic mice are described elsewhere
[12]. For IGF-IR transgene induction, mice were given a
diet containing 2 mg/kg doxycycline (Bio-Serv Inc.,
Frenchtown, NJ). Tumors were allowed to grow to a
maximum length of 17 mm (under the guidelines of the
Canadian Council of Animal Care). IGF-IR-independent
recurrent tumors were formed after the withdrawal of
doxycycline, and are described in [13]. For IGF-IR
downregulation studies, mice harboring mammary
tumors induced through administration of doxycycline
were given a normal diet and tissue was collected 24
and 48 h later. Animals were housed and cared for fol-
lowing guidelines established by the Central Animal
Facility at the University of Guelph and the guidelines
established by the Canadian Council of Animal Care.
Cell lines and culture conditions
RM11A cells, a murine mammary tumor cell line
derived from an MTB-IGFIR mammary tumor, were
grown as described in [24]. Doxycycline (10 μg/mL) was
added to the culture media for transgene induction and
only omitted from the media for withdrawal studies.
RJ345 cells were isolated from primary mammary
tumors of MTB-IGFIR mice and cultured in media con-
taining doxycycine as above while RJ348 and RJ423 cells
were isolated from IGF-IR-independent spindle recur-
rent tumors; all of these cell lines were isolated and cul-
tured in media as described in [24]. Tumors formed
from all cell lines were generated through injection of
approximately 5 × 10
5 cells into the 4
th mammary gland
of syngeneic wild type FVB mice as described in [24].
Tumors were allowed to grow to 17 mm before the ani-
mal was euthanized and tissue was collected.
Western blotting
Western blotting was performed as described in [24].
Briefly, 30 μg of protein lysate was subjected to SDS-
PAGE with subsequent transfer onto nitrocellulose
membranes. Primary antibodies used included anti-
PDGFRa, anti-PDGFRb, anti-phospho-Akt, anti-Akt,
anti-phospho-p42/44, anti-p42/44, anti-Cyclin D1 (all
from Cell Signal technology, Danvers, MA, USA), and
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used at 1:1000 as well as anti-b-actin (Cell Signaling
Technology, Danvers, MA, USA) used at 1:5000. Sec-
ondary antibody was anti-rabbit IgG (Cell Signaling
T e c h n o l o g y ,D a n v e r s ,M A ,U S A )o ra n t i - G o a t( S a n t a
Cruz, Biotechnologies, Santa Cruz, CA) used at 1:2000.
Quantification of protein levels was performed using a
FluorChem 9900 imager and AlphaEaseFC software ver-
sion 3.1.2 (Alpha Innotech, San Leandro, CA, USA).
Immunohistochemistry
Immunohistochemistry was performed as described in
[ 2 5 ] .S e c t i o n sc u tf r o mp r i m a r ya n dI G F - I R - d e v o i d
recurrent tumors describedi n[ 1 3 ]w e r eu s e d .A n t i b o -
dies used were anti-PDGFRa and anti-PDGFRb; both
were used at 1:100 (Cell Signaling Technology, Danvers,
MA, USA). Biotinylated anti-rabbit secondary antibody
(Sigma-Aldrich, St. Louis, MO) was used for both at a
concentration of 1:200. Images were captured using
light microscopy.
Real time PCR
Real time PCR was performed to quantify transcript
levels. RNA was isolated using a mirVANA kit (Ambion,
Streetsville, ON) in accordance with the manufacturer’s
instructions (without the miRNA enrichment step).
Reverse transcription and real time PCR was performed
as described in [13]. Primers specific genes encoding
human IGF-IR [13], as well as PDGFRa and PDGFRb
(both obtained from Origene, Rockville, MD) were used.
The hypoxanthine-guanine phosphoribosyltransferase
(HPRT) gene was used for normalization.
Transfections and siRNA-mediated protein knockdown
Transient transfections were performed using Lipofecta-
mine (Invitrogen, Burlington, ON) in accordance with
the manufacturer’s directions. RNA oligonucleotides
were transfected at a final concentration of 200 pmol/
mL. Briefly, three Stealth siRNA oligonucleotides with
binding specificity for murine IGF-IR, PDGFRa or
PDGFRb mRNA (Invitrogen, Burlington, ON) were ori-
ginally tested for their ability to diminish expression of
these gene products through western blotting. An
appropriate GC control oligonucleotide (Invitrogen, Bur-
lington, ON) was used as a negative control.
MTT survival assays
MTT survival assays were performed as described in [24].
Briefly, 500 cells/well were plated in 96-well plates in tri-
plicate. Two days after seeding, cells were transfected
with siRNA as indicated above. Three days later, MTT
was added to the cells which were subsequently lysed
after 1 h. Values are reported relative to the correspond-
ing GC control and represent the average of 5 trials.
Immunofluorescence
Immunofluorescence was performed as described in
[25]. To assess proliferation, cells plated on coverslips
were transfected with siRNA oligonucleotides specific
for PDGFRa, PDGFRb or both as described above.
Forty-eight hours after siRNA treatement, cells were
fixed with 10% formalin for 1 h at room temperature
and stained for Ki67. Primary antibody, anti-Ki67
(Abcam, Cambridge, MA), was used at a concentration
of 1:200, while antibodies specific for cleaved Caspase-3
and phospho-HistoneH3 (both from Abcam, Cambridge,
MA) were both used at 1:100; fluorescent conjugated
Alexafluor secondary antibody (Invitrogen, Burlington,
ON) was used at a dilution of 1:2000. Images were
taken using using an Olympus BX61 fluorescent micro-
scope (Center Valley, PA) with MetaMorph version
7.6.0.0 software (Molecular Devices, Downington, PA) at
a magnification of 100×. Positive nuclei from 5-10 fields
of view were counted; results represent the average posi-
tivity compared to respective controls from three inde-
pendent trials.
JC-1 assays
JC-1 assays were employed to test apoptosis after
downregulation of PDGFRs. Recurrent cell lines were
plated in 12-well plates. Twenty-four hours later cells
were transfected with RNAi as outlined above. Forty-
eight hours post-transfection, media was removed and
fresh media containing JC-1 (Invitrogen, Burlington,
ON) at a concentration of 200 μg/mL was added to
the cells. Cells were incubated with JC1 for 15 min at
37°C, after which media was removed and wells were
washed three times with PBS. Images were captured
using an Olympus IX81 microscope (Olympus, Mark-
ham, ON) at 200 × magnification using Image Pro
Plus V.5.0.2.9 software (MediaCybernetics, Bethesda,
MD) with the green fluorescent protein (GFP) channel
(485-535 nm).
Scratch assays
For scratch tests, cells were plated in 12-well plates such
that they were 90-100% confluent at the time the
scratch was performed. Transient transfection with
siRNA (as stated above) was performed 48 h after the
cells were seeded. A single scratch was made down the
center of the well with a 200 μL pipette tip 4 h post
transfection. Subsequently media was removed, cells
were washed twice with PBS and media was replaced.
C e l l sw e r ei m a g e da tv a r i o us timepoints (including
immediately after the scratch was produced, 0 h) using
an Olympus IX81 microscope (Olympus, Markham,
ON) at 100 × magnification and Image Pro Plus
V.5.0.2.9 software (MediaCybernetics, Bethesda, MD).
This experiment was replicated four times.
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Recurrent cell lines were transfected with siRNA as
described above. Cell invasion was assessed using 8 μm
BioCoat™ Matrigel invasion chambers (BD Biosciences,
Franklin Lakes, NJ, USA) 24 h after transfection. Cham-
bers were placed in 12-well dishes and the top and bot-
tom compartment were rehydreated with serum free
and full serum media (DMEM containing only gluta-
mine, sodium pyruvate, antibiotic/antimycotic and
HEPES buffer) respectively for two hours at 37°C. Sub-
sequently, 2.0 × 10
4 RJ348 or 1.0 × 10
5 RJ423 cells (pre-
viously transfected) suspended in either 200 or 500 μL
of serum free media were plated in the upper chamber,
while 300 μL of fresh full serum media was added to
the bottom chamber. Invasion was allowed to proceed
for 24 h at 37°C. At this time, 500 μLo f5 %g l u t e r a l d e -
hyde was added to the bottom chamber and invading
cells were fixed for 10 min. Subsequently, wells were
washed three times with distilled water and incubated
with 0.5% toluidine blue for 20 min. Liquid was then
aspirated from both chambers and the lower chamber
was washed three times with water. A cotton swab was
used to wipe the inner surface of the upper chamber to
remove non-invasive cells. Invading cells were visualized
and images were captured using an Olympus IX81
microscope (Olympus, Markham, ON) at 20 × magnifi-
cation and Image Pro Plus V.5.0.2.9 software (MediaCy-
bernetics, Bethesda, MD). Cells were counted from 3-4
fields of view and the average number of invading cells
per field of view was expressed relative to respective
controls. Results represent the average of three
replicates.
Statistics
Results are presented as the mean ± standard error. Sta-
tistical significance was assessed through either a stu-
dent’s t-test (for analyzing two means) or analysis of
variance (ANOVA) followed by a post hoc Tukey test
(for more than two means).
Results
PDGFRs are overexpressed in IGF-IR-independent
mammary tumors
A previous study from our lab showed that downregula-
tion of the IGF-IR transgene in established mammary
tumors in MTB-IGFIR transgenic mice resulted in stable
regression of a majority of the tumors, however, a small
proportion of the tumors resumed growth and expressed
only very low levels of IGF-IR [13]. A DNA microarray
was then performed on wild type mammary tissue,
mammary tumors induced by high levels of the IGF-IR
transgene (also called primary mammary tumors or
PMTs) and mammary tumors that resumed growth fol-
lowing IGF-IR transgene downregulation that only
expressed low levels of IGF-IR (also called IGF-IR-inde-
pendent recurrent spindle tumors or RSTs). The micro-
array data indicated that both PDGFRa and PDGFRb
were upregulated in the IGF-IR-independent, recurrent
tumors compared to the IGF-IR-dependent, primary
tumors [14]. Based on these findings it was hypothesized
that PDGFR overexpression is important for tumor sur-
vival following IGF-IR downregulation.
As a first step, western blotting was performed for
PDGFRa and PDGFRb in primary mammary tumors
(IGF-IR-dependent) and IGF-IR-dependent recurrent
tumors of MTB-IGFIR transgenic mice. Although there
was some inter-tumor variability, the IGF-IR-independent
recurrent spindle tumors displayed an overall increase in
both PDGFRa and PDGFRb, with some tumors displaying
especially high levels (Figure 1a). Expression of PDGFRs
was also assessed using immunohistochemistry. In primary
tumors, only sparse expression of both PDGFRa and b
was observed (Figure 1b-e) while in IGF-IR-independent
recurrent tumors, these receptors were often found to be
highly expressed (Figure 1f-i).
PDGFRs are inversely regulated with IGF-IR expression
T od e t e r m i n ei fP D G F R sw e r er a p i d l yu p r e g u l a t e di n
response to IGF-IR downregulation, MTB-IGFIR trans-
g e n i cm i c ew i t hp a l p a b l em a m m a r yt u m o r sw e r e
switched to normal food (not containing doxycycline).
IGF-IR levels were previously shown to decrease dramati-
cally at 24 h and 48 h following doxycycline withdrawal
[13]. As shown in Figure 2a, both PDGFRa and PDGFRb
were observed to increase at both time points evaluated
(24 h and 48 h). Consistent with the western blot data,
qRT-PCR analysis revealed that IGF-IR mRNA was sig-
nificantly decreased in the mammary tumors following
doxycycline withdrawal while the levels of PDGFRa and
PDGFRb mRNA were elevated at least 2.9-fold (Table 1).
To further validate the induction of PDGFRa and
PDGFRb following IGF-IR transgene downregulation
several cell lines were utilized. First, a cell line estab-
lished from a primary, IGF-IR-dependent mammary
tumor (RJ345) and two cell lines from unique IGF-IR-
independent recurrent tumors (RJ348 and RJ423) were
examined. The RJ345 cells maintained high levels of
IGF-IR while the RJ348 and RJ423 cells expressed much
lower levels of IGF-IR. Consistent with the in vivo find-
ings, tumor cells expressing low levels of IGF-IR (RJ348
and RJ423) expressed high levels of PDGFRa and
PDGFRb compared to the RJ345 cells (Figure 2b).
Next, the RM11A cell line was examined in vitro and
in vivo. The RM11A cell line was also established from
a MTB-IGFIR mammary tumor and this cell line has
been more extensively characterized [23]. The RM11A
cells express high levels of IGF-IR when cultured in the
presence of doxycycline and only express low levels of
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both in vitro and in vivo [24]. In addition, the RM11A
cells can be injected into the mammary fat pad of syn-
geneic, FVB mice and these cells form mammary tumors
faster in the presence of doxycycline than in the absence
of doxycycline [23]. Evaluation of PDGFRa and
PDGFRb in RM11A cells grown in vitro in the presence
of doxycycline or in four independent clones grown in
the absence of doxycycline for at least four passages
revealed that both PDGFRa and PDGFRb levels
increased in the clones expressing low levels of IGF-IR
(Figure 2c). A similar increase in PDGFRa and PDGFRb
levels was observed in RM11A cells grown in vivo in the
absence of doxycycline compared to RM11A cells grown
in vivo in the presence of doxycycline (Figure 2d).
Downregulation of PDGFRs in IGF-IR-independent
recurrent cell lines results in increased survival
To further evaluate the function of PDGFRa and
PDGFRb in mammary tumor cells that have become
independent of IGF-IR signaling, PDGFRa or PDGFRb
were knocked down alone, or in combination, in two
IGF-IR-independent mammary tumor cell lines, RJ348
and RJ423. These two cell lines were chosen as they
express high levels of PDFGRa and PDGFRb and low
levels of IGF-IR (Figure 2b).
Downregulation of PDGFRa or b alone or in combi-
nation was consistently achieved in both cell lines and
was validated up to 72 h post transfection (Figure 3).
Knockdown of either receptor isoform did not result
in downregulation of the other. Concomitant adminis-
tration of siRNA for PDGFRa and PDGFRb was effec-
tive at reducing the expression of both PDFGRs
(Figure 3).
Interestingly, with PDGFR knockdown, Akt activation
increased in both recurrent cell lines (Figure 3). With
pErk1/2, levels increased with PDGFR knockdown in
RJ348 cells; however, in RJ423 cells, this protein was
observed to have slightly decreased levels. Cyclin D1, an
important molecule in our model [12,24], was
Figure 1 IGF-IR independence is associated with upregulation of PDGFRs. Spindle recurrent tumors, formed after doxycycline withdrawal
from MTB-IGFIR mice harbouring tumors and subsequent tumor regression, were compared to primary mammary tumors in which the IGF-IR
transgene was expressed. Western blotting revealed an upregulation in PDGFRa and PDGFRb in spindle recurrent tumors (a). For the western
blots, b-actin served as a loading control. Immunohistochemistry was also used to examine PDGFR expression in two different primary mammary
tumors (b-e) and in two different IGF-IR independent recurrent tumors (f-i). Scale bar = 100 μm.
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Three trials were performed to confirm these findings.
It was expected that given the dramatic increase in
PDGFR expression in recurrent tumors and cells, this
pathway would be important for cell proliferation and
survival. To test this hypothesis, MTT assays were
performed. Contrary to expectations, cell number
increased by approximately 1.7 and 1.5-fold with
PDGFRa knockdown in RJ348 and RJ423 cells, respec-
tively. A more modest 1.4 and 1.2-fold increase in cell
number was observed with downregulation of PDGFRb,
while dual knockdown increased cell number by 2.0 and
Figure 2 PDGF receptors are inversely regulated with IGF-IR. Western blotting was used to examine expression in response to varying IGF-IR
levels. Doxycycline was withdrawn from MTB-IGFIR mice with mammary tumors and tissue was collected 24 or 48 h later. Levels of PDGFRs were
assessed and compared to that of tumors with IGF-IR induction (a). IGF-IR and PDGFR expression in a cell line (RJ345) created from a IGF-IR-
dependent primary mammary tumor and two cell lines (RJ348 and RJ348) created from different IGF-IR-independent recurrent spindle tumors
(b). Four cell clones expressing low levels of IGF-IR were generated through serial passage in the absence of doxycycline. Confirmation of IGF-IR
downregulation as well as determination of PDGFRa and PDGFRb levels was performed (c). PDGFR levels in RM11A cells grown in vivo with
(RM11A + dox) or without (RM11A-dox) doxycycline induction. Tissue was collected when tumors reached 17 mm in diameter (d). For all
Western blots, b-actin served as a loading control.
Table 1 Expression of PDGFR transcripts after suppression of IGF-IR levels
RM11A cell line (in vitro) IGF-IR PDGFRa PDGFRb
with doxycycline 1.000 ± 0.000 1.000 ± 0.000 1.000 ± 0.000
without doxycycline 0.042 ± 0.024 1.608 ± 1.087 2.953 ± 0.534
MTB-IGFIR transgenic (in vivo)
Control 1.000 ± 0.223 1.000 ± 0.392 1.000 ± 0.210
24 h doxycycline withdrawal 0.010 ± 0.006 3.113 ± 1.620 3.193 ± 0.948
48 h doxycycline withdrawal 0.004 ± 0.002 7.527 ± 2.475* 2.917 ± 0.818
*Statistically significant compared to control (with doxycycline) p < 0.05.
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4a). To determine if this effect was due to changes in
proliferation or apoptosis, subsequent assays were
performed.
Apoptosis was addressed by using both JC-1 assays
and staining for cleaved caspase-3 after knocking down
PDGFRs. JC1 assays are based on the detection of loss
of mitochondrial membrane potential, a hallmark of
apoptosis, using a lipophilic cationic dye 5,5’,6 , 6 ’-tetra-
chloro-1,1’,3,3’ -tetraethylbenzimidazolcarbocyanide dye
(JC-1); this dye naturally exhibits a green fluorescence
during low membrane potential, but changes to red
fluorescence as membrane potential increases. Thus
cells staining intensely green are counted as apoptotic
[ 2 6 ] .A ss e e ni nF i g u r e4 ba n d4 c ,k n o c k d o w no f
PDGFRa resulted in a substantial decrease in apoptosis
in both cell lines, while PDGFRb downregulation
resulted in a more modest insignificant decrease in
apoptosis. Little further decrease in apoptosis, compared
to PDGFRa knockdown, was observed when both iso-
forms were targeted as assessed through both aforemen-
tioned assays (Figure 4b, c).
Proliferation after PDGFR downregulation was quanti-
fied through staining for Ki67, a well-known marker of
proliferation, and phosphorylated HistoneH3. As seen in
Figure 4d and 4e, PDGFRa as well as dual PDGFR
knockdown resulted in an almost identical increase in
relative Ki67 and pHistoneH3 positivity of approximately
1.6-fold and 1.3-fold respectively in both cell lines. In
RJ348 cells, PDGFRb had no effect on Ki67 positivity. In
RJ423 cells, knockdown of this receptor isoform had vari-
able results with an average overall increase in Ki67
staining of approximately 1.8-fold (Figure 4d). PDGFRb
knockdown had only a minimal effect on phospho-Histo-
neH3 staining in both cell lines (Figure 4e). Only down-
regulation of both PDGFR isoforms resulted in a
significant increase in proliferation (Figure 4d, e).
PDGFR knockdown in recurrent cell lines impairs
migration and invasion
To assess the importance of PDGFRs for cell migration
in these recurrent cell lines, scratch wound assays were
employed after downregulation of PDGFRs. Images were
captured at various timepoints after the scratch wound
was made and images shown are representative of four
trials (Figure 5). As shown, in the RJ348 cell line, con-
trol cells had penetrated the wound by 14 h and wounds
were observed to be virtually filled by 28 h. With knock-
down of either PDGFRa or b, a slight impairment was
observed after 14 h; however, after 28 h no differences
were seen compared to control cells. When both recep-
tor isoforms were downregulated, cells did not begin to
fill the wound until after 14 h and even after 28 h,
many large gaps devoid of cells were observed (Figure
5a). For RJ423 cells a similar trend was observed; a dra-
matic reduction in migration was observed after knock-
ing down individual PDGFR isoforms or both isoforms
at the first timepoint, 16 h. At the second timepoint, 40
Figure 3 siRNA mediated downregulation of PDGFRs. RJ348 and RJ423 recurrent cell lines were plated and 48 h later they were transiently
transfected with oligonucleotides specific for either PDGFRa, b or both; an appropriate GC oligonucleotide was used as a control. Seventy-two
hours post-transfection, protein was collected and subjected to western blotting probing for both PDGF receptors as well as pAkt, Akt, pErk1/2,
Erk1/2 and cyclin D1. b-actin served as a loading control.
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with knockdown of either PDGFRa or b, relatively large
gaps were still observed and with dual knockdown, very
little progress had been made in filling the wound (Fig-
ure 5b). With knockdown of either PDGFR isoform, it
took approximately 45 h for the wound to be completely
filled, while with dual knockdown, wounds finally were
filled by 72 h (data not shown).
A system utilizing matrigel coated membranes was
employed to assess the role of PDGFRs in extracellular
Figure 4 Downregulation of PDGFRs in IGF-IR-independent recurrent cells increased cell number. MTT assays were performed to examine
cell proliferation/survival after siRNA-mediated knockdown of PDGFRa and b alone or in combination (a). Cell number is expressed relative to
transfection with the control oligonucleotide and represents the average of five trials. JC1 assays were used to assess apoptosis. Cells were
plated in 12-well dishes and transfected with siRNA oligonucleotides specific to PDGFR. JC1 was added after 48 h and fluorescent green cells
were quantified. Results represent the average of 3-4 trials relative to controls (b). Apoptosis was also evaluated by immunofluorescence staining
for cleaved Caspase-3 (c). Proliferation was quantified using immunofluorescence staining for Ki67 (d) and phosphorylated HistoneH3 (e). For all
three above assays, cells were plated in 6-well dishes on coverslips and transfected as above. Fixing and staining was performed 48 h post
transfection. Images were collected at 100 × magnification and positive nuclei were counted. Results represent the average percent positivity
relative to controls for three individual trials (d, e, f). * = p < 0.05 (relative to respective control).
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using siRNA alone or in combination 48 h after plating either RJ348 or RJ423 cells (depicted in a and b respectively). Four hours later a pipette
tip was used to scratch a wound down the middle of the cultured cells (time 0 h, depicted above). Images were captured at 40 × magnification
using an inverted bright field microscope at varying time points after the scratch was made. Representative results are shown; the assay was
repeated four times. Scale bars = 1 mm.
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ure 6a). Downregulation of PDGFRa in both cell lines
resulted in a statistically significant decrease in inva-
sion of approximately 70%, while PDGFRb knock-
down inhibited invasion by approximately 40% (not
determined to be statistically significant) (Figure 6b).
Dual knockdown of both PDGFR isoforms resulted in
an even greater increase in invasion inhibition
compared to downregulation of either isoform alone
(92% and 88% inhibition for RJ348 and RJ423
respectively).
Discussion
While IGF-IR-targeting drugs hold promise for the
treatment of breast cancer, based on what is known of
other such targeted therapeutics, resistance is sure to be
a major roadblock for the treatment of certain patients.
Our work on the MTB-IGFIR transgenic mice supports
the hypothesis that some tumors, although initially
dependent on IGF-IR signaling for growth, can become
independent of IGF-IR signaling. We found that down-
regulation of the IGF-IR transgene (through removal of
doxycycline) in established mammary tumors led to the
Figure 6 Knockdown of PDGFRs inhibited invasion in recurrent cell lines. Matrigel coated chambers were used to assess cell invasion after
PDGFR siRNA. Cells were transfected with siRNA and 24 h later, cells were lifted, resuspended in serum free media and added to the upper
chamber of the matrigel insert; full serum media was added to the bottom well. After 24 h, cells passing through the matrigel coated
membrane were fixed and stained with toluidine blue. Representative images for each condition are shown (a). Scale bar = 50 μm. The average
number of invading cells per field of view was calculated and related back to respective controls (b). Results represent the average of 3
replicates. * = p < 0.05.
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Page 10 of 13regression of most of the mammary tumors. However
approximately 11% of the tumors resumed growth fol-
lowing IGF-IR transgene downregulation and these
tumors no longer expressed high levels of IGF-IR [13].
Analysis at both the mRNA and protein level revealed
that PDGFRa and PDGFRb were consistently upregu-
lated in tumor cells and tumor tissue following loss of
IGF-IR expression. Therefore, one change that occurs
during IGF-IR independent tumor growth is the upregu-
lation of PDGFR signaling.
Although this reciprocal expression pattern has not
been described previously in breast cancer, it has been
observed in a rhabdomyosarcoma cell line selected for
resistance to BMS-754807 (an IGF-IR small molecule
inhibitor) [27]. In this study, administration of increas-
i n gc o n c e n t r a t i o n so fB M S - 7 5 8 0 7t oR h 4 1c e l l sf o r
approximately 5 months resulted in the generation of a
clone resistant to BMS-754807. The BMS-754907-resis-
tant clone expressed lower levels of IGF-IR and elevated
levels of PDGFRa compared to the parental cells. In
addition, the investigators found that the combination of
an anti-IGF-IR agent with an anti-PDGFRa agent
resulted in synergistic cell kill [27]. A reciprocal rela-
tionship between IGF-IR and PDGFRa/c-kit expression
has also been observed in gastrointestinal stromal
tumors [28]. Therefore, it appears that PDGFR signaling
is enhanced following the loss of IGF-IR signaling and
vice versa, an important concept to considering when
designing therapeutic strategies targeting either of these
receptors.
To determine the functional consequence of elevated
PDGFRa and PDGFR b, cell survival, proliferation,
apoptosis and migration/invasion were evaluated follow-
ing RNAi-mediated knockdown of PDGFRa and PDGFR
b alone or concomitant knockdown of both receptors.
The most dramatic effect was the decrease in migration
and invasion following concomitant knockdown of both
PDGFRs. In other systems, PDGFRb has previously been
shown to promote cell migration, while PDGFRa has
been shown to inhibit this process [29-31]. However,
more recently, it was shown that both receptors could
promote migration in fibroblasts with additive effects
when both were present [18]. Similar to these results,
the greatest inhibitory effect on migration was observed
in this study when both isoforms were knocked down
compared to either one individually. Analogous to our
findings, in human breast cancer cell lines, PDGF
ligands have also previously been shown to mediate
invasion or upregulate markers of invasion [32,33].
These processes are important for metastasis and it will
be interesting to determine if the PDGF-axis is involved
in metastasis in our model, especially during IGF-IR-
independent recurrence. Previously, in a model of ras-
transformed mammary epithelial cells undergoing EMT,
PDGFR inhibition was shown to impede metastasis [22].
Somewhat surprisingly, downregulation of both
PDGFRs resulted in a modest increase in proliferation
and a decrease in apoptosis. These results are not in
accordance with conventional models of PDGFR signal-
ing. Typically this pathway is involved in survival and
proliferation for mesenchymal cells including a number
of cancers of mesenchymal origin such as dermatofibro-
sarcoma protuberans, gastrointestinal stromal tumors,
chronic myeloid leukemias and gliomas [15,34]. How-
ever, the mitogenic and transforming effect of PDGFRs
in other tumor types of epithelial origin, including
breast cancer, remains largely unknown. While targeting
the PDGFR usually results in inhibition of cell survival
[35], similar results to ours have been reported in other
models; PDGFRa overexpression was shown to inhibit
melanoma tumor cell growth in vitro and in vivo [36],
while overexpression of PDGF-BB in human pancreatic
and colorectal cells resulted in a reduction in tumor
growth [37].
Interestingly, the levels of phosphorylated Akt were
elevated in both cell lines following downregulation of
PDGFRs. This observation is in contrast to published
reports indicating that PDGFRs signal via Akt [38], but
would explain why an increase in proliferation and a
decrease in apoptosis was observed following PDGFR
downregulation. Phosphorylated Akt initiates signals
that promote cell proliferation and inhibits apoptosis
[39-41]. Therefore, activation of a signaling pathway
other than the PDGFRs must compensate for the loss of
IGF-IR signaling and maintain high levels of Akt phos-
phorylation in our model. One logical receptor family
would be the EGFR/ErbB family as these receptors have
been shown to mediate resistance to IGF-IR targeting
agents in some models [42-44]. However, western blot-
ting of IGF-IR-dependent and IGF-IR-independent
mammary tumors did not show any consistent differ-
ences in the levels of EGFR, ErbB2 or ErbB3 or the
phosphorylated forms of these receptors (data not
shown).
Recently we have shown that mammary tumors that
become independent of IGF-IR signaling in MTB-IGFIR
transgenic mice and the RJ348 cell line have characteris-
tics of claudin-low breast tumors [14,45]. The claudin-
low breast cancer subtype was identified in 2007 and is
characterized by low levels of claudins 3, 4 and 7 as well
as other tight junction proteins [46,47]. Claudin-low
tumors also express high levels of markers associated
with epithelial-to-mesenchymal transition (EMT) such
as Twist1/2, Zeb1/2, Slug and Snail while expressing lit-
tle or no markers of luminal differentiation [46]. The
prevalence of claudin-low tumors is reported to be
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Page 11 of 137-14% and claudin-low tumors have a prognosis similar
to luminal B, HER2 enriched and basal-like breast can-
cers [47]. Claudin-low subtypes have been reported to
most closely resemble mammary epithelial stem cells
[47]. Therefore, it is possible that claudin-low tumors
present with elevated levels of PDGFRa and PDGFRb,a
characteristic that may improve the treatment of this
class of tumor.
In conclusion, loss of IGF-IR signaling is associated
with an increase in PDGFRa and PDGFRb expression.
This increase in PDGFRs appears to enhance migration
and invasion of mammary tumor cells. This phenom-
enon could have important clinical implications in that
treatment with anti-IGFIR agents may result in an
increase in PDGFR expression and enhanced metastatic
capacity of breast cancer cells. Therefore, it may be
important to combine anti-IGF-IR strategies with agents
inhibiting PDGFR signaling to effectively eradicate
tumor cells and to prevent metastasis of any tumor cells
that become resistant to the anti-IGFIR therapy. Alter-
natively, elevation of PDGFRs may be a characteristic of
claudin-low tumors and this feature may be exploited to
improve the treatment of this breast cancer subtype.
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